Literature DB >> 7247378

Cephamycin C treatment of induced swine salmonellosis.

T M Jacks, C J Welter, G R Fitzgerald, B M Miller.   

Abstract

Weanling pigs in groups of 12 were infected orally with Salmonella choleraesuis and were treated intramuscularly with doses of cephamycin C ranging from 12.5 to 337.5 mg twice daily for 10 days beginning 1 day postinoculation. Pigs in two other infected groups either received 300 mg of tetracycline orally on a similar schedule or served as nonmedicated controls. Optimal responses to cephamycin C were achieved at a twice daily dose of 112.5 mg. With this regimen, the febrile response was significantly reduced on day 2 and eliminated by day 5 postinfection, and the shedding of Salmonella spp. in feces was eliminated by day 5 postinfection; essentially, no lesions were found in the gastrointestinal tract at necropsy (day 26 postinfection). There was no mortality among recipients of the 112.5-mg dose; diarrhea was present on only 2% of the observation days. In contrast, 83% of the infected, nonmedicated pigs and 25% of the tetracycline-medicated pigs died, and diarrhea was present in these groups on 63 and 54% of the observation days, respectively. The striking benefits of cephamycin C treatment was achieved without adverse reactions. The weight gain and feed efficiency of the infected pigs treated with the 112.5-mg dose of cephamycin C and the noninfected, nonmedicated control pigs were equivalent.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7247378      PMCID: PMC181477          DOI: 10.1128/AAC.19.4.562

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparison of furazolidone and carbadox in the feed for treatment of Salmonella choleraesuis in swine.

Authors:  L D Olson; D E Rodabaugh; L G Morehouse
Journal:  Am J Vet Res       Date:  1977-10       Impact factor: 1.156

Review 2.  Salmonellosis in swine and its control.

Authors:  L G Morehouse
Journal:  J Am Vet Med Assoc       Date:  1972-02-15       Impact factor: 1.936

3.  Effect of chlortetracycline-sulfamethazine water medication against experimentally induced swine salmonellosis.

Authors:  W Culbreth; K L Simkins; G O Gale; R E Messersmith; B T Alford
Journal:  J Am Vet Med Assoc       Date:  1972-02-15       Impact factor: 1.936

4.  Embolization complicating radial artery puncture.

Authors:  J I Matthews; R B Gibbons
Journal:  Ann Intern Med       Date:  1971-07       Impact factor: 25.391

5.  Salmonella infection in pigs.

Authors:  E A Gibson
Journal:  Br Vet J       Date:  1969-09

6.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

7.  Observations on experimental oral infection with Salmonella dublin in calves and Salmonella choleraesuis in pigs.

Authors:  H W Smith; J E Jones
Journal:  J Pathol Bacteriol       Date:  1967-01

8.  Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; H Kropp; E O Stapley; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

9.  Cephamycins, a new family of beta-lactam antibiotics. 3. In vitro studies.

Authors:  A K Miller; E Celozzi; B A Pelak; E O Stapley; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

10.  Cephamycins, a new family of beta-lactam antibiotics: antibacterial activity and resistance to beta-lactamase degradation.

Authors:  D R Daoust; H R Onishi; H Wallick; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

View more
  1 in total

1.  Attenuation and immunogenicity of Deltacya Deltacrp derivatives of Salmonella choleraesuis in pigs.

Authors:  M J Kennedy; R J Yancey; M S Sanchez; R A Rzepkowski; S M Kelly; R Curtiss
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.